Orion Oyj:製品開発パイプライン動向2015

◆英語タイトル:Orion Oyj - Product Pipeline Review - 2015
◆発行会社(調査会社):Global Markets Direct
Single UserUSD1,500 ⇒換算¥165,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD4,500 ⇒換算¥495,000見積依頼/購入/質問フォーム

Orion Oyj – Product Pipeline Review – 2015


Global Markets Direct’s, ‘Orion Oyj – Product Pipeline Review – 2015’, provides an overview of the Orion Oyj’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Orion Oyj’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides brief overview of Orion Oyj including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Orion Oyj’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Orion Oyj’s pipeline products

Reasons to buy

- Evaluate Orion Oyj’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Orion Oyj in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Orion Oyj’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Orion Oyj and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Orion Oyj
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Orion Oyj and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues


Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Orion Oyj Snapshot 6
Orion Oyj Overview 6
Key Information 6
Key Facts 6
Orion Oyj – Research and Development Overview 7
Key Therapeutic Areas 7
Orion Oyj – Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products – Monotherapy 11
Pipeline Products – Combination Treatment Modalities 12
Pipeline Products – Out-Licensed Products 13
Out-Licensed Products/Combination Treatment Modalities 14
Orion Oyj – Pipeline Products Glance 15
Orion Oyj – Late Stage Pipeline Products 15
Phase III Products/Combination Treatment Modalities 15
Orion Oyj – Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Orion Oyj – Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
Orion Oyj – Drug Profiles 20
(budesonide + formoterol fumarate) 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
(fluticasone propionate + salmeterol) 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
levosimendan 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
ODM-201 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
dexmedetomidine hydrochloride 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ODM-204 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ODM-104 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
ODM-106 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ODM-203 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
ORM-10103 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Small Molecules to Inhibit BET Bromodomain for Oncology 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Small Molecules for Pain 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Orion Oyj – Pipeline Analysis 34
Orion Oyj – Pipeline Products by Target 34
Orion Oyj – Pipeline Products by Route of Administration 35
Orion Oyj – Pipeline Products by Molecule Type 36
Orion Oyj – Pipeline Products by Mechanism of Action 37
Orion Oyj – Recent Pipeline Updates 38
Orion Oyj – Dormant Projects 42
Orion Oyj – Discontinued Pipeline Products 43
Discontinued Pipeline Product Profiles 43
deramciclane 43
nitecapone 43
ODM-102 43
ORM-10921 43
Orion Oyj – Company Statement 44
Orion Oyj – Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 49
Disclaimer 50

[List of Tables]
Orion Oyj, Key Information 6
Orion Oyj, Key Facts 6
Orion Oyj - Pipeline by Indication, 2015 9
Orion Oyj - Pipeline by Stage of Development, 2015 10
Orion Oyj - Monotherapy Products in Pipeline, 2015 11
Orion Oyj - Combination Treatment Modalities in Pipeline, 2015 12
Orion Oyj - Out-Licensed Products in Pipeline, 2015 13
Orion Oyj - Out-Licensed Products/ Combination Treatment Modalities, 2015 14
Orion Oyj - Phase III, 2015 15
Orion Oyj - Phase II, 2015 16
Orion Oyj - Phase I, 2015 17
Orion Oyj - Preclinical, 2015 18
Orion Oyj - Discovery, 2015 19
Orion Oyj - Pipeline by Target, 2015 34
Orion Oyj - Pipeline by Route of Administration, 2015 35
Orion Oyj - Pipeline by Molecule Type, 2015 36
Orion Oyj - Pipeline Products by Mechanism of Action, 2015 37
Orion Oyj - Recent Pipeline Updates, 2015 38
Orion Oyj - Dormant Developmental Projects,2015 42
Orion Oyj - Discontinued Pipeline Products, 2015 43
Orion Oyj, Other Locations 46
Orion Oyj, Subsidiaries 47

[List of Figures]
Orion Oyj - Pipeline by Top 10 Indication, 2015 8
Orion Oyj - Pipeline by Stage of Development, 2015 10
Orion Oyj - Monotherapy Products in Pipeline, 2015 11
Orion Oyj - Out-Licensed Products in Pipeline, 2015 13
Orion Oyj - Pipeline by Top 10 Target, 2015 34
Orion Oyj - Pipeline by Top 10 Route of Administration, 2015 35
Orion Oyj - Pipeline by Top 10 Molecule Type, 2015 36
Orion Oyj - Pipeline Products by Top 10 Mechanism of Action, 2015 37


Orion Oyj、製品開発、製薬、医薬品、治験、研究開発、パイプライン

★調査レポート[Orion Oyj:製品開発パイプライン動向2015] (コード:GMDHC06962CDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[Orion Oyj:製品開発パイプライン動向2015]についてメールでお問い合わせ